New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.
EP. 2: Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.
EP. 3: Treatment Selection in Second Line R/R DLBCL By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.
EP. 4: Tafasitamab and Lenalidomide for R/R DLBCL By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.
EP. 5: Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.
EP. 6: The Role of CAR T-Cell Therapy in R/R DLBCL By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.
EP. 7: Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.
EP. 8: Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.
EP. 9: Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.
EP. 10: Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.
EP. 11: Bispecifics for Third Line Therapy of R/R DLBCL By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.
EP. 12: R/R DLBCL: Safety Considerations for Bispecific Antibodies By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.
EP. 13: Treatment Sequencing of Later Line Therapies in R/R DLBCL By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.
EP. 14: Additional Data Updates from ASH 2023 By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.
EP. 15: Future Outlooks in the Treatment of R/R DLBCL By Sonali Smith, MD, Krish Patel, MD, Lorenzo Falchi, MD, Elizabeth Budde, MD, PhD, Haifaa Abdulhaq, MD, Jason Westin, MD Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
